Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
The Lancet (2021) - Comments
pubmed: 34863358  doi: 10.1016/s0140-6736(21)02717-3  issn: 1474-547x  issn: 0140-6736 

Alasdair P S Munro, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Karishma Gokani, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A Van Der Klaauw, Jonathan Kwok, Vincenzo Libri